Drug Profile


Alternative Names: AEB-1102; AERase; Co-ArgI-PEG - Aeglea Biotherapeutics; Co-ArgI-PEG modified human arginase I - Aeglea Biotherapeutics; Optimised human arginase I - Aeglea Biotherapeutics; PEG-arginase - Aeglea Biotherapeutics; Pegarginase - Aeglea Biotherapeutics

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aeglea Biotherapeutics
  • Class Antineoplastics; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperargininemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hyperargininemia
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 23 May 2017 Aeglea Biotherapeutics receives an information request from the FDA for AEB 1102 in Arginase I deficiency
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 17 Jan 2017 Initial efficacy data from a phase I trial in Hyperargininaemia released by Aeglea BioTherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top